AC Immune Announces Positive Preliminary Phase 1 Data for NLRP3 Inhibitor ACI-19764
AC Immune has announced positive early findings from its Phase 1 study of a new NLRP3 inhibitor, known as ACI-19764. While further details remain behind a paywall, the initial results signal hopeful progress for this experimental approach.
2 days ago
1 min read